Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 10—October 2012
Dispatch

Human Parvovirus 4 in Nasal and Fecal Specimens from Children, Ghana

Jan Felix Drexler, Ulrike Reber, Doreen Muth, Petra Herzog, Augustina Annan, Fabian Ebach, Nimarko Sarpong, Samuel Acquah, Julia Adlkofer, Yaw Adu-Sarkodie, Marcus Panning, Egbert Tannich, Jürgen May, Christian Drosten, and Anna Maria Eis-HübingerComments to Author 
Author affiliations: University of Bonn Medical Centre, Bonn, Germany (J.F. Drexler, U. Reber, D. Muth, A. Annan, F. Ebach, C. Drosten, A.M. Eis-Hübinger); Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany (P. Herzog, J. Adlkofer, E. Tannich, J. May); Kumasi Centre for Collaborative Research in Tropical Medicine, Kumasi, Ghana (A. Annan, N. Sarpong, S. Acquah); Kwame Nkrumah University of Science and Technology, Kumasi (Y. Adu-Sarkodie); and Freiburg University Medical Center, Freiburg, Germany (M. Panning)

Main Article

Table

Nucleotide sequence divergence of parvovirus 4 strains from nasal swab and fecal samples from children, Ghana, from genotype 1, 2, and 3 prototype strains*

Specimen type and no. Nucleotide position according to GenBank accession no. EU874248 Nucleotide sequence divergence from parvovirus 4 reference strains, %
Genotype 1 (GenBank AY622943) Genotype 2 BR10627–5 (GenBank DQ873390) Genotype 3 NG-OR (GenBank EU874248)
Nasal swab

N1

1700–4660 6.56 7.39 0.92

N2

299–4660 7.51 8.07 0.88

N3

50–4660 7.37 8.38† 0.83

N4

1962–2056‡ 9.16 6.73 2.14

N4

2117–3413 4.97 5.31 0.93

N5

1962–2056 9.16 6.73 2.14

N5

2117–4183 5.50 6.34 0.98

N6

299–4660 7.51 8.10 0.90

N7

1962–2056 9.16 6.73 2.14

N7

2431–2914 6.24 7.01 1.25

N7

3068–3246 4.61 5.19 1.12

N8

624–3246 7.36 7.84 0.84
Feces

F1

1700–4183 6.20 6.82 0.89

F2

1700–4460 6.56 7.39 0.92

F3

1700–3716 6.08 6.52 0.85

F4

1700–4183 6.02 6.78 0.89

F5

1700–4183 6.93 6.73 1.04

*Pairwise nucleotide divergence was calculated by using the DNA distance matrix in BioEdit (www.mbio.ncsu.edu/BioEdit/bioedit.html).
†Because the homologs of the first 92 nt of strain N3 are not given in the prototype strain BR10627–5, calculation of divergence started at N3 nt position 93.
‡Nucleotide sequence of the PCR product (primer sequences trimmed) was amplified by using screening PCR designed for detection of PARV4 genotype 3 as described (7).

Main Article

References
  1. Jones  MS, Kapoor  A, Lukashov  VV, Simmonds  P, Hecht  F, Delwart  E. New DNA viruses identified in patients with acute viral infection syndrome. J Virol. 2005;79:82306. DOIPubMed
  2. Fryer  JF, Lucas  SB, Padley  D, Baylis  SA. Parvoviruses PARV4/5 in hepatitis C virus–infected patient. Emerg Infect Dis. 2007;13:1756. DOIPubMed
  3. Simmonds  P, Manning  A, Kenneil  R, Carnie  FW, Bell  JE. Parenteral transmission of the novel human parvovirus PARV4. Emerg Infect Dis. 2007;13:13868. DOIPubMed
  4. Sharp  CP, Lail  A, Donfield  S, Simmons  R, Leen  C, Klenerman  P, High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis. 2009;200:111925. DOIPubMed
  5. Lahtinen  A, Kivela  P, Hedman  L, Kumar  A, Kantele  A, Lappalainen  M, Serodiagnosis of primary infections with human parvovirus 4, Finland. Emerg Infect Dis. 2011;17:7982. DOIPubMed
  6. Sharp  CP, Vermeulen  M, Nebie  Y, Djoko  CF, LeBreton  M, Tamoufe  U, Epidemiology of human parvovirus 4 infection in sub-Saharan Africa. Emerg Infect Dis. 2010;16:16057. DOIPubMed
  7. Panning  M, Kobbe  R, Vollbach  S, Drexler  JF, Adjei  S, Adjei  O, Novel human parvovirus 4 genotype 3 in infants, Ghana. Emerg Infect Dis. 2010;16:11436. DOIPubMed
  8. Yang  SJ, Hung  CC, Chang  SY, Lee  KL, Chen  MY. Immunoglobulin G and M antibodies to human parvovirus 4 (PARV4) are frequently detected in patients with HIV-1 infection. J Clin Virol. 2011;51:647. DOIPubMed
  9. Benjamin  LA, Lewthwaite  P, Vasanthapuram  R, Zhao  G, Sharp  C, Simmonds  P, Human parvovirus 4 as potential cause of encephalitis in children, India. Emerg Infect Dis. 2011;17:14847.PubMed
  10. Yu  X, Zhang  J, Hong  L, Wang  L, Yuan  Z, Zhang  X, High prevalence of human parvovirus 4 infection in HBV and HCV infected individuals in Shanghai. PLoS ONE. 2012;7:e29474. DOIPubMed
  11. Lurcharchaiwong  W, Chieochansin  T, Payungporn  S, Theamboonlers  A, Poovorawan  Y. Parvovirus 4 (PARV4) in serum of intravenous drug users and blood donors. Infection. 2008;36:48891. DOIPubMed
  12. Simmonds  P, Douglas  J, Bestetti  G, Longhi  E, Antinori  S, Parravicini  C, A third genotype of the human parvovirus PARV4 in sub-Saharan Africa. J Gen Virol. 2008;89:2299302. DOIPubMed
  13. Fryer  JF, Delwart  E, Hecht  FM, Bernardin  F, Jones  MS, Shah  N, Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion. 2007;47:105461. DOIPubMed
  14. Sharp  CP, Lail  A, Donfield  S, Gomperts  ED, Simmonds  P. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion. 2012;52:14829. DOIPubMed
  15. Manning  A, Russell  V, Eastick  K, Leadbetter  GH, Hallam  N, Templeton  K, Epidemiological profile and clinical associations of human bocavirus and other human parvoviruses. J Infect Dis. 2006;194:128390. DOIPubMed

Main Article

Page created: October 05, 2012
Page updated: October 05, 2012
Page reviewed: October 05, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external